• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由痘苗病毒 Ankara 株(MVA)中强病毒启动子驱动的基因表达通过增强抗体反应和暴露 CD8⁺ T 细胞表位来提高疫苗接种效率。

Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8⁺ T Cell Epitopes.

作者信息

Becker Pablo D, Nörder Miriam, Weissmann Sebastian, Ljapoci Ronny, Erfle Volker, Drexler Ingo, Guzmán Carlos A

机构信息

Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, D-38124 Braunschweig, Germany.

Institute of Virology, Technische Universität München, D-81675 Munich, Germany.

出版信息

Vaccines (Basel). 2014 Jul 22;2(3):581-600. doi: 10.3390/vaccines2030581.

DOI:10.3390/vaccines2030581
PMID:26344747
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4494220/
Abstract

Viral vectors are promising tools for vaccination strategies and immunotherapies. However, CD8⁺ T cell responses against pathogen-derived epitopes are usually limited to dominant epitopes and antibody responses to recombinant encoded antigens (Ags) are mostly weak. We have previously demonstrated that the timing of viral Ag expression in infected professional Ag-presenting cells strongly shapes the epitope immunodominance hierarchy. T cells recognizing determinants derived from late viral proteins have a clear disadvantage to proliferate during secondary responses. In this work we evaluate the effect of overexpressing the recombinant Ag using the modified vaccinia virus early/late promoter H5 (mPH5). Although the Ag-expression from the natural promoter 7.5 (P7.5) and the mPH5 seemed similar, detailed analysis showed that mPH5 not only induces higher expression levels than P7.5 during early phase of infection, but also Ag turnover is enhanced. The strong overexpression during the early phase leads to broader CD8 T cell responses, while preserving the priming efficiency of stable Ags. Moreover, the increase in Ag-secretion favors the induction of strong antibody responses. Our findings provide the rationale to develop new strategies for fine-tuning the responses elicited by recombinant modified vaccinia virus Ankara by using selected promoters to improve the performance of this viral vector.

摘要

病毒载体是疫苗接种策略和免疫疗法中很有前景的工具。然而,针对病原体衍生表位的CD8⁺ T细胞反应通常仅限于显性表位,并且对重组编码抗原(Ag)的抗体反应大多较弱。我们之前已经证明,感染的专职抗原呈递细胞中病毒抗原表达的时间强烈影响表位免疫优势等级。识别源自晚期病毒蛋白的决定簇的T细胞在二次反应期间增殖明显处于劣势。在这项工作中,我们评估了使用改良痘苗病毒早期/晚期启动子H5(mPH5)过表达重组抗原的效果。尽管来自天然启动子7.5(P7.5)和mPH5的抗原表达看起来相似,但详细分析表明,mPH5不仅在感染早期诱导的表达水平高于P7.5,而且抗原周转也得到增强。早期的强烈过表达导致更广泛的CD8 T细胞反应,同时保持稳定抗原的启动效率。此外,抗原分泌的增加有利于诱导强烈的抗体反应。我们的研究结果为开发新策略提供了理论依据,即通过使用选定的启动子来微调重组改良安卡拉痘苗病毒引发的反应,以提高这种病毒载体的性能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/e7b721878f13/vaccines-02-00581-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/fc548cab173e/vaccines-02-00581-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/8efc1db9c83b/vaccines-02-00581-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/e2b3529e81dd/vaccines-02-00581-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/d37bff8893c6/vaccines-02-00581-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/1f7d261cb6c9/vaccines-02-00581-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/83f44f1849e4/vaccines-02-00581-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/e7b721878f13/vaccines-02-00581-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/fc548cab173e/vaccines-02-00581-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/8efc1db9c83b/vaccines-02-00581-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/e2b3529e81dd/vaccines-02-00581-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/d37bff8893c6/vaccines-02-00581-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/1f7d261cb6c9/vaccines-02-00581-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/83f44f1849e4/vaccines-02-00581-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e4/4494220/e7b721878f13/vaccines-02-00581-g007.jpg

相似文献

1
Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8⁺ T Cell Epitopes.由痘苗病毒 Ankara 株(MVA)中强病毒启动子驱动的基因表达通过增强抗体反应和暴露 CD8⁺ T 细胞表位来提高疫苗接种效率。
Vaccines (Basel). 2014 Jul 22;2(3):581-600. doi: 10.3390/vaccines2030581.
2
Analysis of MHC Class I Processing Pathways That Generate a Response to Vaccinia Virus Late Proteins.对产生针对痘苗病毒晚期蛋白反应的MHC I类加工途径的分析。
Immunohorizons. 2019 Dec 2;3(12):559-572. doi: 10.4049/immunohorizons.1900074.
3
Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.DNA 启动的 RNA 复制子和改良安卡拉痘苗病毒 HCV 疫苗接种诱导小鼠产生强效抗丙型肝炎病毒 (HCV) T 细胞免疫应答。
J Virol. 2019 Mar 21;93(7). doi: 10.1128/JVI.00055-19. Print 2019 Apr 1.
4
Modified Vaccinia Virus Ankara Can Induce Optimal CD8 T Cell Responses to Directly Primed Antigens Depending on Vaccine Design.改良安卡拉痘苗病毒可根据疫苗设计诱导直接刺激抗原的最佳 CD8 T 细胞应答。
J Virol. 2019 Oct 15;93(21). doi: 10.1128/JVI.01154-19. Print 2019 Nov 1.
5
Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.尽管宿主基因表达降低,但在小鼠中引发高免疫原性的丙型肝炎疫苗候选物 MVA-HCV 中去除 C6 痘苗病毒干扰素-β抑制剂。
Viruses. 2018 Aug 8;10(8):414. doi: 10.3390/v10080414.
6
Immunisation of cattle against Babesia bovis combining a multi-epitope modified vaccinia Ankara virus and a recombinant protein induce strong Th1 cell responses but fails to trigger neutralising antibodies required for protection.牛巴贝斯虫的多表位修饰痘苗安卡拉病毒和重组蛋白联合免疫可诱导强烈的 Th1 细胞反应,但不能产生保护所需的中和抗体。
Ticks Tick Borne Dis. 2019 Oct;10(6):101270. doi: 10.1016/j.ttbdis.2019.101270. Epub 2019 Aug 16.
7
Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.重组改良安卡拉痘苗病毒人体试验中痘病毒特异性CTL的免疫显性
J Immunol. 2005 Dec 15;175(12):8431-7. doi: 10.4049/jimmunol.175.12.8431.
8
Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.嵌合H5血凝素可引发针对流感病毒的广泛体液免疫和细胞免疫反应。
J Virol. 2016 Jul 11;90(15):6771-6783. doi: 10.1128/JVI.00730-16. Print 2016 Aug 1.
9
Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.用纯化融合蛋白初免并以改良安卡拉痘苗病毒(MVA-TAB)重组体加强免疫后,针对HIV-1 Env的V3环多表位多肽(TAB13)的增强CD8 + T细胞免疫反应:与痘苗病毒西储株(WR)载体的体液免疫和细胞免疫反应比较
Vaccine. 2001 Dec 12;20(5-6):961-71. doi: 10.1016/s0264-410x(01)00389-9.
10
Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination.CD8+ T细胞的交叉竞争在加强疫苗接种过程中塑造免疫显性等级。
J Exp Med. 2007 Sep 3;204(9):2187-98. doi: 10.1084/jem.20070489. Epub 2007 Aug 20.

引用本文的文献

1
Advancements, challenges, and future perspectives in developing feline herpesvirus 1 as a vaccine vector.开发猫疱疹病毒 1 作为疫苗载体的进展、挑战和未来展望。
Front Immunol. 2024 Sep 12;15:1445387. doi: 10.3389/fimmu.2024.1445387. eCollection 2024.
2
Viral Vector-Based Vaccines Encoding CTH522 Induce Distinct Immune Responses in C57BL/6J and HLA Transgenic Mice.编码CTH522的基于病毒载体的疫苗在C57BL/6J和HLA转基因小鼠中诱导不同的免疫反应。
Vaccines (Basel). 2024 Aug 22;12(8):944. doi: 10.3390/vaccines12080944.
3
Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice.

本文引用的文献

1
Clinical development of Modified Vaccinia virus Ankara vaccines.安卡拉痘苗病毒改良疫苗的临床研发。
Vaccine. 2013 Sep 6;31(39):4241-6. doi: 10.1016/j.vaccine.2013.03.020. Epub 2013 Mar 21.
2
Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.鼻咽癌患者中表达 Epstein-Barr 病毒肿瘤抗原的重组改良安卡拉痘苗病毒的 I 期临床试验。
Cancer Res. 2013 Mar 15;73(6):1676-88. doi: 10.1158/0008-5472.CAN-12-2448. Epub 2013 Jan 24.
3
Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
新设计的痘病毒启动子可提高MVA-NP候选疫苗对小鼠致命性流感病毒感染的免疫原性和效力。
Pathogens. 2023 Jun 23;12(7):867. doi: 10.3390/pathogens12070867.
4
Identification and evaluation of a panel of strong constitutive promoters in Listeria monocytogenes for improving the expression of foreign antigens.鉴定和评价李斯特菌中一组强组成型启动子,用于提高外源抗原的表达。
Appl Microbiol Biotechnol. 2021 Jun;105(12):5135-5145. doi: 10.1007/s00253-021-11374-z. Epub 2021 Jun 4.
5
ORF6 and ORF61 Expressing MVA Vaccines Impair Early but Not Late Latency in Murine Gammaherpesvirus MHV-68 Infection.ORF6 和 ORF61 表达的 MVA 疫苗在小鼠γ疱疹病毒 MHV-68 感染中早期但不晚期损害潜伏。
Front Immunol. 2019 Dec 18;10:2984. doi: 10.3389/fimmu.2019.02984. eCollection 2019.
6
Sequestration of Late Antigens Within Viral Factories Impairs MVA Vector-Induced Protective Memory CTL Responses.晚期抗原在病毒工厂内的隔离会损害 MVA 载体诱导的保护性记忆 CTL 反应。
Front Immunol. 2019 Dec 4;10:2850. doi: 10.3389/fimmu.2019.02850. eCollection 2019.
7
Genomic Characterization of Strain D1701-V () and Development of Novel Sites for Multiple Transgene Expression.D1701-V()株的基因组特征与多个转基因表达新位点的开发
Viruses. 2019 Jan 30;11(2):127. doi: 10.3390/v11020127.
DNA初免与改良安卡拉痘苗病毒-HIV-1 C亚型疫苗加强免疫在健康成年人中的安全性和免疫原性。
Clin Vaccine Immunol. 2013 Mar;20(3):397-408. doi: 10.1128/CVI.00637-12. Epub 2013 Jan 23.
4
MHC class I antigen processing distinguishes endogenous antigens based on their translation from cellular vs. viral mRNA.MHC Ⅰ类抗原加工根据其来源于细胞 mRNA 还是病毒 mRNA 来区分内源性抗原。
Proc Natl Acad Sci U S A. 2012 May 1;109(18):7025-30. doi: 10.1073/pnas.1112387109. Epub 2012 Apr 16.
5
Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.树突状细胞暴露于基于 MVA 的 HIV-1 疫苗可诱导 HIV-1 感染个体中具有高度功能性的 HIV-1 特异性 CD8(+) T 细胞应答。
PLoS One. 2011;6(5):e19644. doi: 10.1371/journal.pone.0019644. Epub 2011 May 18.
6
Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells.安卡拉改良痘苗病毒与树突状细胞的相互作用:旁观者树突状细胞的表型和功能成熟。
J Virol. 2011 Jun;85(11):5532-45. doi: 10.1128/JVI.02267-10. Epub 2011 Mar 16.
7
Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.改良安卡拉痘苗病毒在小鼠模型中发挥强大的免疫调节活性。
PLoS One. 2010 Jun 30;5(6):e11400. doi: 10.1371/journal.pone.0011400.
8
Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.基于改良安卡拉痘苗病毒的 HIV 候选疫苗的临床前研究:抗原呈递和抗病毒作用。
J Virol. 2010 May;84(10):5314-28. doi: 10.1128/JVI.02329-09. Epub 2010 Mar 10.
9
Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes.泛素-蛋白酶体系统的抑制可阻止痘苗病毒DNA复制以及中期和晚期基因的表达。
J Virol. 2009 Mar;83(6):2469-79. doi: 10.1128/JVI.01986-08. Epub 2009 Jan 7.
10
Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo.安卡拉痘苗病毒修饰株在血液淋巴细胞中优先靶向树突状细胞,并在体内诱导病毒特异性T细胞反应中起关键作用。
BMC Immunol. 2008 Apr 15;9:15. doi: 10.1186/1471-2172-9-15.